Sonidegib
Sonidegib (Odomzo, Sun Pharmaceutical Industries Europe B.V.) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Basal cell carcinoma1 | |||
None | Monotherapy | Any line locally adv. | Not amenable to curative surgery or radiation therapy |
Full text of section 4.1 (therapeutic indications)
Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
Label history
14 changes to the Odomzo label since 2016, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes